オフポンプとオンポンプバイパス術技術は同等である(Abstracts # 13-LB-10677 and 13-LB-15974)

CORONARY and GOPCABE:オンポンプおよびオフポンプバイパス術技術の安全性および有効性は同等である
CORONARY and GOPCABE: Similar safety and efficacy with on- and off-pump bypass surgery techniques
第62回American College of Cardiology学会で発表された2つのレイトブレイキングトライアルにおいて、オンポンプおよびオフポンプ冠動脈バイパス術(CABG)の有効性は同等であると発表され同時にNew England Journal of Medicineオンライン版に掲載された。CORONARYスタディは、オンポンプとオフポンプバイパス術を比較した最大規模の国際的多施設トライアルである。このスタディではバイパス術施行を既に予定された患者4,752人を組み入れた。死亡、脳卒中、心筋梗塞または術後1年以内の透析を要する新たな腎不全の複合である一次エンドポイントについては、オフポンプバイパス術を受けた患者とオンポンプバイパス術を受けた患者とで有意差はなかった(12.2%対13.3%、P =0.24)。もう1つの大規模多施設トライアル―GOPCABEと呼ばれるドイツ高齢者におけるオフポンプ冠動脈バイパス術(ドイツの12の心血管医療センターにおいて初回の待機的CABGを予定された75歳以上の患者2,539人を組み入れ)においても同様の結果が報告された。一次エンドポイントは死亡、脳卒中、心発作、血行再建術再試行または術後30日以内の新たな腎移植の複合であった。その結果、オンポンプバイパス術を受けた患者とオフポンプバイパス術を受けた患者とで一次エンドポイントに有意差はなかった(8.2%対7.8%、P =0.74)。
Full Text

A large randomized trial comparing bypass surgery done with a heart-lung machine (on-pump) and without it (off-pump) found no differences in results between techniques overall but some clinically relevant differences, according to research presented at the American College of Cardiology's 61st Annual Scientific Session.

Off-pump coronary artery bypass graft (CABG) surgery eliminates the need to insert a cannula into the aorta, to cross-clamp the aorta, connect the patient to the heart-lung machine, and stop and restart the heart, suggesting that patients would do better with this approach. However, small, randomized clinical trials and meta-analyses have not been able to determine conclusively whether one CABG technique has better outcomes than the other. The CORONARY trial, conducted at 79 centers in 19 countries, compared the risks and benefits of off-pump and on-pump bypass in the largest patient population studied to date. While the CORONARY trial was recruiting patients, data from the ROOBY (Randomized On/Off Bypass) trial were published showing poor results for off-pump bypass. 

"After ROOBY's results, we looked again at our trial design and decided to continue, with the approbation of the Data Safety Monitoring Board," said André Lamy, M.D., Division of Cardiac Surgery at Canada's McMaster University in Hamilton, ON, and one of the study's three lead investigators. "ROOBY was done through the U.S. Veterans Administration at only 18 hospitals. Our trial was international and much larger, it had more women and sicker patients and our surgeons were more experienced in off-pump procedures"

Since October 2007, the CORONARY trial has enrolled 4,752 patients with coronary artery disease who were slated for CABG and randomly assigned to off-pump or on-pump surgery after a complete assessment to make sure they were suitable candidates for both techniques. The mean patient age was 67.6 years, 80.9 percent were men and the average number of grafts was 3.1 per patient.

For the primary composite outcome of death, myocardial infarction, kidney failure and stroke at 30 days post-bypass, the results were statistically neutral: 9.9 percent for off-pump patients and 10.3 percent for the on-pump group. Similarly, no differences were seen for individual events of the composite outcome. These results were a surprise to the researchers. Based on previous meta-analyses, Dr. Lamy and his colleagues expected that off-pump CABG would decrease the rate of stroke and renal failure.

"We found that off-pump did reduce the amount of blood products needed, reoperation for bleeding, pulmonary complications and acute kidney injury, but there was also more revascularization in off-pump patients, meaning that surgery didn't work completely," Dr. Lamy said. This was a rare occurrence (16 of 2,375 patients, or 0.7 percent versus 0.2 percent in the on-pump group), but it is considered a technical failure and requires the patient to return to the operating room for a repeat CABG or for a stent in the cath lab, where imaging systems guide those catheter-based procedures.

"This introduces a new concept in cardiac surgery, allowing patient-specific decisions for bypass surgery," Dr. Lamy said. "Off-pump procedures are trickier and more stressful, and the benefit is for the patient, not the surgeon, so in many places, they're simply not done. My goal is to persuade surgeons to individualize the technique – to do off-pump bypass or on-pump when indicated – so their patients will benefit."

The CORONARY trial will conduct safety and efficacy follow-up at five years and assess total costs and neuro-cognitive results at 30 days and at five years after CABG. The 30-day cost data and neuro-cognitive results are expected within six months.